Producer
Taro Pharmaceutical Industries
One of the world's largest manufacturers of generic topical dermatology products; ~40% market share in US generic corticosteroid creams and ointments; owned by Sun Pharmaceutical Industries (India); manufactures in Israel, Canada, and US; controls a significant share of the US generic topical market for high-potency steroids.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Taro Pharmaceutical Industries supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Taro Pharmaceutical Industries makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Generic Topical Dermatology
60%Generic Oral Pharmaceuticals
25%OTC & Consumer Health
10%Branded Specialty (Limited)
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2023
Taro controls approximately 40% of the US generic topical corticosteroid market -- meaning that when an American dermatologist prescribes clobetasol propionate for severe psoriasis, or triamcinolone for eczema, or halobetasol for inflammatory conditions, there is a ~40% chance the dispensed generic was manufactured at a Taro facility in Brampton Ontario or Hawthorne New York. This single company determines the price and availability of the anti-inflammatory creams used daily by millions of Americans with chronic skin conditions. When a Taro manufacturing line experiences a quality control failure or FDA warning letter (as occurred in 2012-2013), corticosteroid shortages at US pharmacies extend lead times for patients managing psoriasis and eczema flares -- conditions that worsen significantly without consistent medication access.
Taro Pharmaceutical Industries Ltd. ↗Concentration2023
Taro Pharmaceutical is an Israeli company that became the dominant US generic topical dermatology manufacturer — by systematically cornering FDA-approved ANDA rights for corticosteroid creams over 30 years Taro Pharmaceutical Industries was founded in Israel in 1950. Its entry into the US generic market in the 1990s focused specifically on topical dermatology — a segment requiring specialized manufacturing know-how (emulsion stability, skin penetration testing) that deterred generalist pharmaceutical companies. Taro accumulated a library of ~400 US ANDAs, making it the most-ANDA-rich topical pharmaceutical company in the US by the 2010s. Sun Pharmaceutical acquired control of Taro in 2012 (after a contested takeover beginning in 2007). Taro's strategy demonstrates how a niche manufacturing focus can create near-monopoly market positions in dosage forms that are technically complex to manufacture generically.
Taro Pharmaceutical / US SEC ↗Origin2023
Taro Pharmaceutical Industries was founded in 1950 in Haifa as Taro Pharmaceuticals Industries Ltd -- one of the first pharmaceutical manufacturers established in the new State of Israel. It was founded by Abraham and Baruch Levitt, who had immigrated from Poland, and was named 'Taro' (the Hebrew word for 'dew'). Taro grew by manufacturing generic versions of established drugs and exporting them, building expertise in topical formulations (creams, ointments, gels) that require specialized manufacturing. In 2007-2012, Sun Pharmaceutical Industries of India acquired controlling interest in Taro through a protracted takeover battle involving minority shareholder lawsuits. The acquisition made Taro a subsidiary of Sun Pharma, one of India's largest pharmaceutical companies, and is one of the more prominent cases of an Indian company acquiring an Israeli pharmaceutical pioneer.
Taro Pharmaceutical Industries Ltd. ↗